Japanese Fund, Pharma Firm Looking For Investment Opportunities In Israel

November 29, 2017 | ORIX Investment and Management fund and Japanese pharmaceutical company MitsubishiTanabe Pharma are looking for investment opportunities in Israel. The two companies met with the Israel Minister of Economy Eli Cohen, who outlined various opportunities for investing in the Israeli market and emphasized the opportunity to develop strategic cooperation. ORIX, a huge Japanese conglomerate, has already acquired a 22 percent stake in geothermal energy business Ormat for $627 million. It is currently traded at a value of $21 billion on the Japanese stock exchange and has a diversified investment portfolio of companies in the fields of energy, transportation, infrastructure, and real estate in 36 countries. Japanese pharmaceutical company MitsubishiTanabe Pharma recently acquired Israeli pharma company NeuroDerm for $1.1 billion. This acquisition is the largest deal to date between an Israeli company and a Japanese company.